FDA greenlights palopegteriparatide for hypoparathyroidism treatment

Palopegteriparatide (Yorvipath), a parathyroid hormone analog (PTH(1-34)), is a once-daily injection indicated for adults with hypoparathyroidism. Approval was based on data from the phase 3 PaTHway trial, in which 68.9% of palopegteriparatide recipients (n = 61) met the efficacy endpoint at week 26 compared with 4.8% of individuals (n = 21) in the placebo group.